Kazia Therapeutics (KZIA) Notes Payables (2013 - 2025)

Kazia Therapeutics has reported Notes Payables for 5 years, with the latest figure at $64874.3 in Q4 2025.

• For the quarter ending Q4 2025, Notes Payables fell 29.51% year-over-year to $64874.3; the trailing twelve-month figure through Dec 2025 stood at $64874.3 (down 29.51% YoY), and the FY2025 full-year result was $253381.0, down 39.36% from the prior year.
• Notes Payables for Q4 2025 stood at $64874.3, down from $253381.0 in the prior quarter.
• The five-year high for Notes Payables was $1.2 million in Q2 2023, with the low at -$1.3 million in Q2 2022.
• Historically, Notes Payables has averaged $163327.7 across 4 years, with a median of $243640.9 in 2023.
• Annual changes were most pronounced in 2023 — Notes Payables soared 191.03% — and 2024, when it slumped 65.19%.
• Kazia Therapeutics' Notes Payables stood at $362883.0 in 2022, then plunged by 35.54% to $233900.9 in 2023, then plunged by 60.65% to $92035.9 in 2024, then declined by 29.51% to $64874.3 in 2025.
• The last three Notes Payables figures came in at $64874.3 (Q4 2025), $253381.0 (Q2 2025), and $92035.9 (Q4 2024), per Business Quant data.